CHUGAI PHARMACEUTICAL CO.,LTD. (4519.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

21.2x

EV/EBITDA

15.1x

Market Cap

JPY 11.32T

MomentumView details →

1D Return

+0.67%

YTD Return

−17.57%

RSI (14)

42.0

ValuationView details →

P/E (Fwd)

21.2x

EV/EBITDA

15.1x

Market Cap

JPY 11.32T

RSI (14)

42.0

MomentumView details →

1D Return

+0.67%

YTD Return

−17.57%

ProfitabilityView details →

Gross Margin

69.26%

Net Margin

35.02%

EBITDA Margin

—

ROE (TTM)

23.70%

ROA (TTM)

19.96%

Asset Turnover

0.55x

GrowthView details →

Revenue YoY

+5.65%

EPS YoY

+10.24%

FCF YoY

+6.07%

Revenue CAGR 3Y

−0.05%

EPS CAGR 3Y

+5.03%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

4.70x

Quick Ratio

3.82x

Div Yield

2.14%

Div Rate

JPY 272.00

Div Growth 1Y

+177.55%

Financials snapshotView financials →

Revenue (TTM)

1.29T

Net Income (TTM)

452.20B

Op. CF (TTM)

441.64B

Next earningsOct 27, 2026 →

Latest newsMore news →

Daiichi Sankyo's market capitalization fell about 55% from its peak in July 2024 to 5.3707 trillion yen as of September 2, 2026, dropping it to fourth place among Japanese pharmaceutical companies.2d ago

Chugai Pharmaceutical submitted a manufacturing and marketing approval application to Japan's Ministry of Health, Labour and Welfare for its anti-IL-6 monoclonal antibody 'Vamikibart' for the indication of macular edema associated with non-infectious uveitis.7d ago

Similar companies

Takeda Pharmaceutical Company Limited4502.T Otsuka Holdings Co.,Ltd.4578.T DAIICHI SANKYO COMPANY,LIMITED4568.T Astellas Pharma Inc.4503.T Shionogi & Co.,Ltd.4507.T Eisai Co.,Ltd.4523.T Find similar companies →

Latest newsMore news →

Daiichi Sankyo's market capitalization fell about 55% from its peak in July 2024 to 5.3707 trillion yen as of September 2, 2026, dropping it to fourth place among Japanese pharmaceutical companies.2d ago Chugai Pharmaceutical submitted a manufacturing and marketing approval application to Japan's Ministry of Health, Labour and Welfare for its anti-IL-6 monoclonal antibody 'Vamikibart' for the indication of macular edema associated with non-infectious uveitis.7d ago